FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. [Review]

MedStar author(s):
Citation: Clinical Infectious Diseases. 58 Suppl 1:S4-9, 2014 Jan.PMID: 24343831Institution: MedStar Washington Hospital CenterDepartment: Medicine/Pulmonary-Critical CareForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov't | ReviewSubject headings: *Anti-Bacterial Agents/tu [Therapeutic Use] | *Clinical Trials as Topic/st [Standards] | *Skin Diseases, Bacterial/dt [Drug Therapy] | Endpoint Determination/st [Standards] | Guidelines as Topic | Humans | Patient Selection | United States | United States Food and Drug AdministrationYear: 2014Local holdings: Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007ISSN:
  • 1058-4838
Name of journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAbstract: Recent guidance from the US Food and Drug Administration (FDA) on the conduct of clinical trials for acute bacterial skin and skin structure infection (ABSSSI) has 20140821d the framework for clinical trial design and conduct. Notable 140821s included new disease state definitions, new primary endpoint definitions and the timing of assessments at these endpoints, and updated guidance on patient inclusion/exclusion criteria. Supportive evidence and statistical justification for the proposed noninferiority margins were described in detail. Although the updated guidelines are still considered drafts and have been adopted in some trials, they serve as the basis for study protocol discussions between pharmaceutical companies and the FDA in advancing the development of promising new agents. Not only will the new trial designs impact researchers and sponsors responsible for drug development programs, but they will also affect healthcare providers participating in clinical trials and the ways in which clinicians develop patient treatment plans based on the results of those trials. This review provides a summary of key 140821s that will impact future clinical trial design and outcomes.All authors: Itani KM, Shorr AFFiscal year: FY2014Digital Object Identifier: Date added to catalog: 2014-08-21
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24343831 Available 24343831

Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007

Recent guidance from the US Food and Drug Administration (FDA) on the conduct of clinical trials for acute bacterial skin and skin structure infection (ABSSSI) has 20140821d the framework for clinical trial design and conduct. Notable 140821s included new disease state definitions, new primary endpoint definitions and the timing of assessments at these endpoints, and updated guidance on patient inclusion/exclusion criteria. Supportive evidence and statistical justification for the proposed noninferiority margins were described in detail. Although the updated guidelines are still considered drafts and have been adopted in some trials, they serve as the basis for study protocol discussions between pharmaceutical companies and the FDA in advancing the development of promising new agents. Not only will the new trial designs impact researchers and sponsors responsible for drug development programs, but they will also affect healthcare providers participating in clinical trials and the ways in which clinicians develop patient treatment plans based on the results of those trials. This review provides a summary of key 140821s that will impact future clinical trial design and outcomes.

English

Powered by Koha